TORONTO, ON / ACCESSWIRE / February 22, 2021 / Aquarius Surgical Technologies Inc. (CSE:ASTI) (“ASTI” or the “Company”) announces that Gordon Willox has been removed as a director of, and from all offices and positions in Surgical Lasers Inc., the wholly-owned operating subsidiary of the Company, with immediate effect. Steps will also be taken to remove Gordon Willox as a Director of ASTI at the earliest opportunity.
The Company also announces that David Machika has been appointed as C.E.O. of Surgical Lasers Inc., to act jointly with Gary Van Nest.
The Company has given instructions for a full audit and examination of the financial and other records of Surgical Lasers Inc., the results of which will be published when available.
The Company has requested that trading of its shares on the Canadian Securities Exchange be halted pending dissemination of this News Release; trading will resume upon receipt of all relevant regulatory and other approvals.
About Aquarius Surgical Technologies Inc.
Aquarius Surgical Technologies is an exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology. Solutions also include clinical education, service, support and maintenance. ASTI is focused on increasing the availability of services for patients, enhancing the quality of patient care, improving operationally efficiencies and reducing total operational costs.
For more information, please contact:
Gary Van Nest, CEO gary@sinaltainvestments.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Aquarius Surgical Technologies Inc.
View source version on accesswire.com:
https://www.accesswire.com/631075/Aquarius-Surgical-Technologies-Announces-Removal-of-Gordon-Willox-as-Director-and-Officer-of-Surgical-Lasers-Inc
NORTHAMPTON, MA / ACCESSWIRE / June 12, 2024 / Gilead SciencesLuciana Preger credits being exposed…
CHESTNUT HILL, MA / ACCESSWIRE / June 12, 2024 / Nava Health, a leader in…
Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care…
New AI-driven technology integration marks a first in the U.S., enhancing patient access to specialized…
TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…
Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s…